Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Inhibition of the CDK2 and Cyclin A complex leads to autophagic degradation of CDK2 in cancer cells
Jiawei Zhang, Yichao Gan, Hongzhi Li, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 77

Showing 1-25 of 77 citing articles:

Role of LMO7 in cancer (Review)
Qun Zeng, Tingting Jiang, Jing Wang
Oncology Reports (2024) Vol. 52, Iss. 3
Closed Access | Times Cited: 16
Homoharringtonine: mechanisms, clinical applications and research progress
Wen Wang, Lan He, Ting Lin, et al.
Frontiers in Oncology (2025) Vol. 15
Open Access | Times Cited: 2
Development of pyrolo[2,3-c]pyrazole, pyrolo[2,3-d]pyrimidine and their bioisosteres as novel CDK2 inhibitors with potent in vitro apoptotic anti-proliferative activity: Synthesis, biological evaluation and molecular dynamics investigations
Eman M. Azmy, Mohamed Hagras, Menna A. Ewida, et al.
Bioorganic Chemistry (2023) Vol. 139, pp. 106729-106729
Closed Access | Times Cited: 31
TRIM21‐Promoted FSP1 Plasma Membrane Translocation Confers Ferroptosis Resistance in Human Cancers
Jun Gong, Yuhui Liu, Wenjia Wang, et al.
Advanced Science (2023) Vol. 10, Iss. 29
Open Access | Times Cited: 23
Novel tetrahydroisoquinolines as DHFR and CDK2 inhibitors: synthesis, characterization, anticancer activity and antioxidant properties
Eman M. Sayed, Etify A. Bakhite, Reda Hassanien, et al.
BMC Chemistry (2024) Vol. 18, Iss. 1
Open Access | Times Cited: 10
CDK2 and CDK4: Cell Cycle Functions Evolve Distinct, Catalysis-Competent Conformations, Offering Drug Targets
Wengang Zhang, Yonglan Liu, Hyunbum Jang, et al.
JACS Au (2024) Vol. 4, Iss. 5, pp. 1911-1927
Open Access | Times Cited: 10
DNMT1-targeting remodeling global DNA hypomethylation for enhanced tumor suppression and circumvented toxicity in oral squamous cell carcinoma
Yangfan Liu, Yu Sun, Jin Yang, et al.
Molecular Cancer (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 10
Slower CDK4 and faster CDK2 activation in the cell cycle
Wengang Zhang, Yonglan Liu, Hyunbum Jang, et al.
Structure (2024) Vol. 32, Iss. 8, pp. 1269-1280.e2
Closed Access | Times Cited: 9
Synthesis and Anticancer Evaluation of O-Alkylated (E)-Chalcone Derivatives: A Focus on Estrogen Receptor Inhibition
Alwah R. Al-Ghamdi, Wahid U. Ahmed, Reem I. Al-Wabli, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 2, pp. 833-833
Open Access | Times Cited: 1
Development of allosteric and selective CDK2 inhibitors for contraception with negative cooperativity to cyclin binding
Erik B. Faber, Luxin Sun, Jian Tang, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 21
Screening through Lead Optimization of High Affinity, Allosteric Cyclin-Dependent Kinase 2 (CDK2) Inhibitors as Male Contraceptives That Reduce Sperm Counts in Mice
Erik B. Faber, Nan Wang, Kristen John, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 3, pp. 1928-1940
Closed Access | Times Cited: 19
TRIM21 induces selective autophagic degradation of c-Myc and sensitizes regorafenib therapy in colorectal cancer
Wenlong Ye, Long Huang, Xiaoqin Yang, et al.
Proceedings of the National Academy of Sciences (2024) Vol. 121, Iss. 42
Open Access | Times Cited: 8
DFT Analyses of arsylsemicarbazone group as functional compound for application as excellent fluorescent probes and medicament: study on virtual screening through molecular docking
Debosreeta Bose, Akash Sil, Parna Chakraborty, et al.
Chemical Papers (2024) Vol. 78, Iss. 10, pp. 6069-6082
Open Access | Times Cited: 6
The emerging roles of TRIM21 in coordinating cancer metabolism, immunity and cancer treatment
Xintian Chen, Menghan Cao, Pengfei Wang, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 27
Machine Learning-Based Virtual Screening and Molecular Simulation Approaches Identified Novel Potential Inhibitors for Cancer Therapy
Muhammad Shahab, Guojun Zheng, Abbas Khan, et al.
Biomedicines (2023) Vol. 11, Iss. 8, pp. 2251-2251
Open Access | Times Cited: 16
Identification of core therapeutic targets for Monkeypox virus and repurposing potential of drugs against them: An in silico approach
Anshuman Sahu, Mahendra Gaur, Nimai Charan Mahanandia, et al.
Computers in Biology and Medicine (2023) Vol. 161, pp. 106971-106971
Open Access | Times Cited: 13
Autophagy modulation in cancer therapy: Challenges coexist with opportunities
Yongya Wu, Aoxue Wang, Guotai Feng, et al.
European Journal of Medicinal Chemistry (2024) Vol. 276, pp. 116688-116688
Closed Access | Times Cited: 5
Characteristics of anticancer activity of CBP/p300 inhibitors – Features of their classes, intracellular targets and future perspectives of their application in cancer treatment
Magdalena Strachowska, Agnieszka Robaszkiewicz
Pharmacology & Therapeutics (2024) Vol. 257, pp. 108636-108636
Open Access | Times Cited: 4
TarIKGC: A Target Identification Tool Using Semantics-Enhanced Knowledge Graph Completion with Application to CDK2 Inhibitor Discovery
Shen Xiao-juan, Shijia Yan, Tao Zeng, et al.
Journal of Medicinal Chemistry (2025)
Closed Access
Metastatic melanoma: An integrated analysis to identify critical regulators associated with prognosis, pathogenesis and targeted therapies
Zeinab Chaharlashkar, Yousof Saeedi Honar, Meghdad Abdollahpour‐Alitappeh, et al.
PLoS ONE (2025) Vol. 20, Iss. 1, pp. e0312754-e0312754
Open Access
Anti-Proliferative Activity of Ethylenediurea Derivatives with Alkyl and Oxygen-Containing Groups as Substituents
Maxim Oshchepkov, L. V. Kovalenko, Antonida V. Kalistratova, et al.
Biomedicines (2025) Vol. 13, Iss. 2, pp. 316-316
Open Access
Unraveling a novel therapeutic facet of Etravirine to confront Hepatocellular Carcinoma via disruption of cell cycle
Gouri Nair, G.R. Saraswathy, Jesil Mathew Aranjani, et al.
Scientific Reports (2025) Vol. 15, Iss. 1
Open Access
MiR-192-2 Regulates the Proliferation and Apoptosis of Ovarian Granulosa Cells by Targeting IGFBP2 in Zhedong White Geese
Size Wang, Chunyu Zeng, Yue Pan, et al.
Animals (2025) Vol. 15, Iss. 5, pp. 663-663
Open Access
Licoisoflavone a Inhibits Colorectal Cancer Cell Proliferation Through Targeting Cdk2-Cyclin E1 Axis-Mediated Cell Cycle Transition
Jingwei Cui, Hao Chen, Yuru Chen, et al.
(2025)
Closed Access
Targeting cyclin-dependent kinase 2 (CDK2) interactions with cyclins and Speedy 1 (Spy1) for cancer and male contraception
Jeanine Giarolla, Kelsey Holdaway, Maryam Nazari, et al.
Future Medicinal Chemistry (2025), pp. 1-21
Closed Access
Page 1 - Next Page

Scroll to top